Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | PNLIP | P16233 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897262 | 1.00 | NPC1 (0.43) | NPC1RAB9AFFAR1HPGDPTGDR2 | |
| SCHEMBL5897273 | 1.00 | NPC1 (0.43) | NPC1RAB9AFFAR1HPGDPTGDR2 | |
| SCHEMBL5895486 | 0.91 | FFAR1 (0.51) | NPC1RAB9AFFAR1HPGDPTGDR2 | |
| SCHEMBL5895496 | 0.91 | FFAR1 (0.51) | NPC1RAB9AFFAR1HPGDPTGDR2 | |
| SCHEMBL5895506 | 0.91 | FFAR1 (0.51) | NPC1RAB9AFFAR1HPGDPTGDR2 | |
| SCHEMBL5895908 | 0.89 | NPSR1 (0.44) | NPC1RAB9AFFAR1HPGDPTGDR2 | |
| SCHEMBL5896356 | 0.89 | HPGD (0.39) | NPC1RAB9AFFAR1HPGDNPSR1 | |
| SCHEMBL5895900 | 0.89 | NPSR1 (0.44) | NPC1RAB9AFFAR1HPGDPTGDR2 | |
| SCHEMBL5895799 | 0.89 | NPSR1 (0.39) | NPC1RAB9AFFAR1HPGDNPSR1 | |
| SCHEMBL5896363 | 0.89 | HPGD (0.39) | NPC1RAB9AFFAR1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041690-B2 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | POLRMT, EIF5B, POLI | NPC1 131/4885RAB9A 1149/4885FFAR1 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.